Endothelial nitric oxide genotypes and haplotypes are not associated with end-stage renal disease

DNA and Cell Biology

Volumn 30, Issue 1, 2011, Pages 55-59

  Marson, Bernardo P ^a   Dickel, Samantha ^b   Ishizawa, Marília H ^a   Metzger, Ingrid F ^a   Izidoro Toledo, Tatiane ^a   Da Costa, Bartira Ercília Pinheiro ^b   Poli De Figueiredo, Carlos E ^b   Tanus Santos, Jose E ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; ENDOTHELIAL NITRIC OXIDE SYNTHASE;

ADULT; ARTICLE; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; DEMOGRAPHY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPE; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC MARKERS; HAPLOTYPES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; NITRIC OXIDE SYNTHASE TYPE III; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 78651422720     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/dna.2010.1106     Document Type: Article

References (37)

1. Asakimori, Y., Yorioka, N., Yamamoto, I., Okumoto, S., Doi, S., Hirai, T., and Taniguchi, Y. (2001). Endothelial nitric oxide synthase intron 4 polymorphism influences the progression of renal disease. Nephron 89, 219-223.
2. Bellini, M.H., Figueira, M.N., Piccoli, M.F., Marumo, J.T., Cen-doroglo, M.S., Neto, M.C., Dalboni, M.A., Batista, M.C., Goes, M.A., and Schor, N. (2007). Association of endothelial nitric oxide synthase gene intron 4 polymorphism with end-stage renal disease. Nephrology (Carlton) 12, 289-293.
3. Buraczynska, M., Ksiazek, P., Zaluska, W., Nowicka, T., and Ksiazek, A. (2004). Endothelial nitric oxide synthase gene in-tron 4 polymorphism in patients with end-stage renal disease. Nephrol Dial Transplant 19, 2302-2306.
4. Crawford, D.C., and Nickerson, D.A. (2005). Definition and clinical importance of haplotypes. Annu Rev Med 56, 303-320.
5. Guzik, T.J., Black, E., West, N.E., McDonald, D., Ratnatunga, C., Pillai, R., and Channon, K.M. (2001). Relationship between the G894T polymorphism (Glu298Asp variant) in endothelial nitric oxide synthase and nitric oxide-mediated endothelial function in human atherosclerosis. Am J Med Genet 100, 130-137.
6. Kawachi, S., Hines, I.N., Laroux, F.S., Hoffman, J., Bharwani, S., Gray, L., Leffer, D., and Grisham, M.B. (2000). Nitric oxide synthase and postischemic liver injury. Biochem Biophys Res Commun 276, 851-854.
7. Kerkeni, M., Letaief, A., Achour, A., Miled, A., Trivin, F., and Maaroufi, K. (2009). Endothelial nitric oxide synthetase, me- thylenetetrahydrofolate reductase polymorphisms, and cardiovascular complications in Tunisian patients with nondiabetic renal disease. Clin Biochem 42, 958-964.
8. Kone, B.C., and Baylis, C. (1997). Biosynthesis and homeostatic roles of nitric oxide in the normal kidney. Am J Physiol 272, F561-F578.
9. Lacchini, R., Silva, P.S., and Tanus-Santos, J.E. (2010). A phar-macogenetics-based approach to reduce cardiovascular mortality with the prophylactic use of statins. Basic Clin Pharmacol Toxicol 106, 357-361.
10. Liu, Y., Burdon, K.P., Langefeld, C.D., Beck, S.R., Wagenknecht, L.E., Rich, S.S., Bowden, D.W., and Freedman, B.I. (2005). T-786C polymorphism of the endothelial nitric oxide synthase gene is associated with albuminuria in the diabetes heart study. J Am Soc Nephrol 16, 1085-1090.
11. Luizon, M.R., Izidoro-Toledo, T.C., Simoes, A.L., and Tanus-Santos, J.E. (2009). Endothelial nitric oxide synthase polymorphisms and haplotypes in Amerindians. DNA Cell Biol 28, 329-334.
12. Mamoulakis, D., Bitsori, M., Galanakis, E., Vazgiourakis, V., Panierakis, C., and Goulielmos, G.N. (2009). Intron 4 polymorphism of the endothelial nitric oxide synthase eNOS gene and early microangiopathy in type 1 diabetes. Int J Im-munogenet 36, 153-157.
13. McClellan, W.M., and Flanders, W.D. (2003). Risk factors for progressive chronic kidney disease. J Am Soc Nephrol 14, S65-S70.
14. Metzger, I.F., Sertorio, J.T., and Tanus-Santos, J.E. (2007). Modulation of nitric oxide formation by endothelial nitric oxide synthase gene haplotypes. Free Radic Biol Med 43, 987-992.
15. Metzger, I.F., Souza-Costa, D.C., Marroni, A.S., Nagassaki, S., Desta, Z., Flockhart, D.A., and Tanus-Santos, J.E. (2005). En-dothelial nitric oxide synthase gene haplotypes associated with circulating concentrations of nitric oxide products in healthy men. Pharmacogenet Genomics 15, 565-570.
16. Morita, T., Ito, H., Suehiro, T., Tahara, K., Matsumori, A., Chi-kazawa, H., Nakauchi, Y., Nishiya, K., and Hashimoto, K. (1999). Effect of a polymorphism of endothelial nitric oxide synthase gene in Japanese patients with IgA nephropathy. Clin Nephrol 52, 203-209.
17. Nagase, S., Suzuki, H., Wang, Y., Kikuchi, S., Hirayama, A., Ueda, A., Takada, K., Oteki, T., Obara, M., Aoyagi, K., and Koyama, A. (2003). Association of ecNOS gene polymorphisms with end stage renal diseases. Mol Cell Biochem 244, 113-118.
18. Nagassaki, S., Herculano, R.D., Graeff, C.F., and Tanus-Santos, J.E. (2009). eNOS T-786C polymorphism affects atorvastatin-induced changes in erythrocyte membrane fluidity. Eur J Clin Pharmacol 65, 385-392.
19. Nagassaki, S., Metzger, I.F., Souza-Costa, D.C., Marroni, A.S., Uzuelli, J.A., and Tanus-Santos, J.E. (2005). eNOS genotype is without effect on circulating nitrite/nitrate level in healthy male population. Thromb Res 115, 375-379.
20. Nagassaki, S., Sertorio, J.T., Metzger, I.F., Bem, A.F., Rocha, J.B., and Tanus-Santos, J.E. (2006). eNOS gene T-786C polymorphism modulates atorvastatin-induced increase in blood nitrite. Free Radic Biol Med 41, 1044-1049.
21. Noiri, E., Satoh, H., Taguchi, J., Brodsky, S.V., Nakao, A., Oga-wa, Y., Nishijima, S., Yokomizo, T., Tokunaga, K., and Fujita, T. (2002). Association of eNOS Glu298Asp polymorphism with end-stage renal disease. Hypertension 40, 535-540.
22. Remuzzi, G., Benigni, A., and Remuzzi, A. (2006). Mechanisms of progression and regression of renal lesions of chronic ne-phropathies and diabetes. J Clin Invest 116, 288-296.
23. Sandrim, V.C., Coelho, E.B., Nobre, F., Arado, G.M., Lanchote, V.L., and Tanus-Santos, J.E. (2006a). Susceptible and protective eNOS haplotypes in hypertensive black and white subjects. Atherosclerosis 186, 428-432.
24. Sandrim, V.C., de Syllos, R.W., Lisboa, H.R., Tres, G.S., and Tanus-Santos, J.E. (2006b). Endothelial nitric oxide synthase haplotypes affect the susceptibility to hypertension in patients with type 2 diabetes mellitus. Atherosclerosis 189, 241-246.
25. Sandrim, V.C., de Syllos, R.W., Lisboa, H.R., Tres, G.S., and Tanus-Santos, J.E. (2007). Influence of eNOS haplotypes on the plasma nitric oxide products concentrations in hypertensive and type 2 diabetes mellitus patients. Nitric Oxide 16, 348-355.
26. Sandrim, V.C., Palei, A.C., Cavalli, R.C., Araujo, F.M., Ramos, E.S., Duarte, G., and Tanus-Santos, J.E. (2008). eNOS haplo-types associated with gestational hypertension or preeclamp-sia. Pharmacogenomics 9, 1467-1473.
27. Sandrim, V.C., Palei, A.C., Luizon, M.R., Izidoro-Toledo, T.C., Cavalli, R.C., and Tanus-Santos, J.E. (2010a). eNOS haplotypes affect the responsiveness to antihypertensive therapy in pre-eclampsia but not in gestational hypertension. Pharmacoge-nomics J 10, 40-45.
28. Sandrim, V.C., Palei, A.C., Sertorio, J.T., Cavalli, R.C., Duarte, G., and Tanus-Santos, J.E. (2010b). Effects of eNOS polymorphisms on nitric oxide formation in healthy pregnancy and in pre-eclampsia. Mol Hum Reprod 16, 506-510.
29. Sandrim, V.C., Yugar-Toledo, J.C., Desta, Z., Flockhart, D.A., Moreno, H., Jr., and Tanus-Santos, J.E. (2006c). Endothelial nitric oxide synthase haplotypes are related to blood pressure elevation, but not to resistance to antihypertensive drug therapy. J Hypertens 24, 2393-2397.
30. Sarnak, M.J., Levey, A.S., Schoolwerth, A.C., Coresh, J., Culleton, B., Hamm, L.L., McCullough, P.A., Kasiske, B.L., Kelepouris, E., Klag, M.J., Parfrey, P., Pfeffer, M., Raij, L., Spinosa, D.J., and Wilson, P.W. (2003). Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108, 2154-2169. (Pubitemid 37337595)
31. Schmidt, R.J., and Baylis, C. (2000). Total nitric oxide production is low in patients with chronic renal disease. Kidney Int 58, 1261-1266.
32. Souza-Costa, D.C., Sandrim, V.C., Lopes, L.F., Gerlach, R.F., Rego, E.M., and Tanus-Santos, J.E. (2007). Anti-inflammatory effects of atorvastatin: modulation by the T-786C polymorphism in the endothelial nitric oxide synthase gene. Atherosclerosis 193, 438-444.
33. Stephens, M., and Donnelly, P. (2003). A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73, 1162-1169.
34. Suzuki, H., Nagase, S., Kikuchi, S., Wang, Y., and Koyama, A. (2000). Association of a missense Glu298Asp mutation of the endothelial nitric oxide synthase gene with end stage renal disease. Clin Chem 46, 1858-1860.
35. Tanus-Santos, J.E., Desai, M., and Flockhart, D.A. (2001). Effects of ethnicity on the distribution of clinically relevant endothe-lial nitric oxide variants. Pharmacogenetics 11, 719-725.
36. Vasconcellos, V., Lacchini, R., Jacob-Ferreira, A.L., Sales, M.L., Ferreira-Sae, M.C., Schreiber, R., Nadruz, W., and Tanus-Santos, J.E. (2010). Endothelial nitric oxide synthase hap-lotypes associated with hypertension do not predispose to cardiac hypertrophy. DNA Cell Biol 29, 171-176.
37. Zanchi, A., Moczulski, D.K., Hanna, L.S., Wantman, M., War-ram, J.H., and Krolewski, A.S. (2000). Risk of advanced diabetic nephropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism. Kidney Int 57, 405-413.